Differences in cerebrospinal fluid microRNA profiles in patients with remitting multiple sclerosis and patients with other neurological diseases
https://doi.org/10.14412/2074-2711-2025-2-49-54
Abstract
Objective: to compare microRNA profiles in cerebrospinal fluid (CSF) of patients with remitting multiple sclerosis (RMS) in remission and patients with other neurological diseases.
Material and methods. Eight patients with RMS in remission (4 males and 4 females) and 8 patients with other neurological diseases (4 males and 4 females) were included in the study. We compared the microRNA profiles in the CSF of the patients in the two study groups. Profiling was performed by sequencing small RNAs with the MGISEQ-200 device. The differences in microRNA levels were analyzed using the DESeq2 package for the R programming language. For microRNAs whose levels in CSF differed between the analyzed patient groups, a network of interactions with their target genes was created using the miRNet web service. Common targets were identified from the whole set of targets; for the resulting set of targets, an overrepresentation analysis of the pathways annotated in the KEGG database was performed.
Results. The level of 30 microRNAs differed significantly (padj<0.05; |log2FC|>1) in the analyzed patient groups, the concentration of 13 microRNAs was higher and of 17 – lower in the CSF of patients with multiple sclerosis (MS). The search for common targets of these microRNAs allowed us to identify 8 protein-coding genes, each of which is a target of at least 5 microRNAs from the selected group: MIDN, MDM2, CDKN1A, TMEM184B, TAOK1, HNRNPA, NFIC and ZNF460.
Conclusion. MicroRNA profiles in CSF distinguish patients with MS from patients with other neurological diseases. The possibility of using changes in the concentration of detected microRNAs in CSF as a diagnostic marker for MS needs to be confirmed in independent samples.
About the Authors
М. А. Omarova
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia;
Federal Center for Brain and Neurotechnologies, Federal Medical and Biological Agency of Russia
Russian Federation
Competing Interests:
Russian Federation
1, Ostrovityanova St., Moscow 117513;
1, Ostrovityanova St., Build. 10, Moscow 117513
Competing Interests:
The study was carried out with the financial support of the Russian Science Foundation grant No. 22-15-00284. The investigation has not been sponsored. There are no conflicts of interest. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.
М. S. Kozin
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia;
E.I. Chazov National Medical Research Center for Cardiology, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
1, Ostrovityanova St., Moscow 117513;
15A, Third Cherepkovskaya St., Moscow 121552
Competing Interests:
The study was carried out with the financial support of the Russian Science Foundation grant No. 22-15-00284. The investigation has not been sponsored. There are no conflicts of interest. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.
А. N. Boyko
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia;
E.I. Chazov National Medical Research Center for Cardiology, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
1, Ostrovityanova St., Moscow 117513;
15A, Third Cherepkovskaya St., Moscow 121552
Competing Interests:
The study was carried out with the financial support of the Russian Science Foundation grant No. 22-15-00284. The investigation has not been sponsored. There are no conflicts of interest. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.
References
1. Beer S, Khan F, Kesselring J. Rehabilitation interventions in multiple sclerosis: an overview. J Neurol. 2012 Sep;259(9):1994-2008. doi: 10.1007/s00415-012-6577-4. Epub 2012 Jul 8.
2. GBD 2016 Multiple Sclerosis Collaborators. Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 Mar;18(3):269-85. doi: 10.1016/S1474-4422(18)30443-5. Epub 2019 Jan 21.
3. Cree BAC, Arnold DL, Chataway J, et al. Secondary Progressive Multiple Sclerosis: New Insights. Neurology. 2021 Aug 24;97(8):378-88. doi: 10.1212/WNL.0000000000012323. Epub 2021 Jun 4.
4. Koch M, Kingwell E, Rieckmann P, Tremlett H. The natural history of primary progressive multiple sclerosis. Neurology. 2009 Dec 8;73(23):1996-2002. doi: 10.1212/WNL.0b013e3181c5b47f
5. Koch M, Kingwell E, Rieckmann P, Tremlett H; UBC MS Clinic Neurologists. The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2010 Sep;81(9):1039-43. doi: 10.1136/jnnp.2010.208173. Epub 2010 Jul 16.
6. Huynh JL, Casaccia P. Epigenetic mechanisms in multiple sclerosis: implications for pathogenesis and treatment. Lancet Neurol. 2013 Feb;12(2):195-206. doi: 10.1016/S1474-4422(12)70309-5
7. Bhaskaran M, Mohan M. MicroRNAs: history, biogenesis, and their evolving role in animal development and disease. Vet Pathol. 2014 Jul;51(4):759-74. doi: 10.1177/0300985813502820. Epub 2013 Sep 17.
8. Dexheimer PJ, Cochella L. MicroRNAs: From Mechanism to Organism. Front Cell Dev Biol. 2020 Jun 3;8:409. doi: 10.3389/fcell.2020.00409
9. Zhang L, Ding H, Zhang Y, et al. Circulating MicroRNAs: Biogenesis and Clinical Significance in Acute Myocardial Infarction. Front Physiol. 2020 Sep 3;11:1088. doi: 10.3389/fphys.2020.01088
10. Marabita F, de Candia P, Torri A, et al. Normalization of circulating microRNA expression data obtained by quantitative realtime RT-PCR. Brief Bioinform. 2016 Mar;17(2):204-12. doi: 10.1093/bib/bbv056. Epub 2015 Aug 3.
11. Jagot F, Davoust N. Is It worth Considering Circulating microRNAs in Multiple Sclerosis? Front Immunol. 2016 Apr 5;7:129. doi: 10.3389/fimmu.2016.00129
12. Omarova MA, Kozin MS, Boyko AN. Free circulating miRNA as a potential diagnostic marker in multiple sclerosis (review). Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(1S):29-33. doi: 10.14412/2074-2711-2022-1S-29-33 (In Russ.)
13. Zheleznyakova GY, Piket E, Needhamsen M, et al. Small noncoding RNA profiling across cellular and biofluid compartments and their implications for multiple sclerosis immunopathology. Proc Natl Acad Sci U S A. 2021 Apr 27;118(17):e2011574118. doi: 10.1073/pnas.2011574118
14. Freedman MS, Thompson EJ, Deisenhammer F, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol. 2005 Jun;62(6):865-70. doi: 10.1001/archneur.62.6.865
15. Kozomara A, Birgaoanu M, Griffiths-Jones S. miRBase: from microRNA sequences to function. Nucleic Acids Res. 2019 Jan 8;47(D1):D155-D162. doi: 10.1093/nar/gky1141
16. Chang L, Xia J. MicroRNA Regulatory Network Analysis Using miRNet 2.0. Methods Mol Biol. 2023;2594:185-204. doi: 10.1007/978-1-0716-2815-7_14
17. Munoz-San Martin M, Gomez I, Quiroga-Varela A, et al. miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2022 Dec 9;10(1):e200069. doi: 10.1212/NXI.0000000000200069
18. Ahlbrecht J, Martino F, Pul R, et al. Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsing-remitting multiple sclerosis. Mult Scler. 2016 Aug;22(9):1202-14. doi: 10.1177/1352458515613641. Epub 2015 Oct 22.
19. Munoz-San Martin M, Torras S, Robles-Cedeno R, et al. Radiologically isolated syndrome: targeting miRNAs as prognostic biomarkers. Epigenomics. 2020 Dec;12(23):2065-76. doi: 10.2217/epi-2020-0172. Epub 2020 Dec 8.
20. Munoz-San Martin M, Reverter G, Robles-Cedeno R, et al. Analysis of miRNA signatures in CSF identifies upregulation of miR-21 and miR-146a/b in patients with multiple sclerosis and active lesions. J Neuroinflammation. 2019 Nov 14;16(1):220. doi: 10.1186/s12974-019-1590-5
21. Haghikia A, Haghikia A, Hellwig K, et al. Regulated microRNAs in the CSF of patients with multiple sclerosis: a case-control study. Neurology. 2012 Nov 27;79(22):2166-70. doi: 10.1212/WNL.0b013e3182759621. Epub 2012 Oct 17.
22. Quintana E, Ortega FJ, Robles-Cedeno R, et al. miRNAs in cerebrospinal fluid identify patients with MS and specifically those with lipid-specific oligoclonal IgM bands. Mult Scler. 2017 Nov;23(13):1716-26. doi: 10.1177/1352458516684213. Epub 2017 Jan 9.
23. Kramer S, Haghikia A, Bang C, et al. Elevated levels of miR-181c and miR-633 in the CSF of patients with MS: A validation study. Neurol Neuroimmunol Neuroinflamm. 2019 Oct 1;6(6):e623. doi: 10.1212/NXI.0000000000000623
24. Soldan SS, Lieberman PM. Epstein-Barr virus and multiple sclerosis. Nat Rev Microbiol. 2023 Jan;21(1):51-64. doi: 10.1038/s41579-022-00770-5. Epub 2022 Aug 5.
Review
For citations:
Omarova МА, Kozin МS, Boyko АN. Differences in cerebrospinal fluid microRNA profiles in patients with remitting multiple sclerosis and patients with other neurological diseases. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2025;17(2):49-54. (In Russ.) https://doi.org/10.14412/2074-2711-2025-2-49-54
Views:
82
Email this article 